•🧬GLP-2TZ for research use only:
Optimize your project design with an advanced co-lyophilized research preparation. This specialized compound coordinates two distinct peptide chains within a single unvarying format, allowing laboratories to evaluate overlapping multi-receptor pharmacology configurations and comparative receptor signaling behavior without managing manual ratio preparations at the bench.
•⚙️1. Peptide Overview & Preclinical Stability
The development of this combined matrix pairing secures a highly stable dual-agonist environment. Automated solid-phase peptide synthesis guarantees unvarying compound distribution across each unique reference batch. To safeguard the target structural links from premature chain breakdown, store the dry lyophilized powder tightly sealed inside freezer setups under continuous low-temperature control at -20°C, ensuring the glass container remains completely clear of light or moisture. When initiating test protocols, reconstitute the white cake matrix gently using sterile laboratory solvents. Reconstituted fluid stock solutions require continuous refrigeration at 2-8°C to prevent early peptide cleavage throughout the screening assay window. Fast domestic transport lanes manage preparation and dispatch rapidly to secure optimal chemical longevity upon arrival.
•🔬2. Research Mechanisms & Preclinical FAQ
•📋What specific receptor pathways are evaluated using this multi-component blend?
Preclinical literature monitors functional agonism assays across three distinct pathways simultaneously. The integrated structure allows researchers to study glucagon-like peptide-2 signaling alongside dual incretin receptor-binding readouts, mapping both GIP and GLP-1 cyclic-AMP cellular communication thresholds within transfected cell lines.
•📋How do researchers establish molecular trace verification before assay setups?
Every reference batch connects directly to its lot-matched Certificate of Analysis (COA). Independent testing networks verify a purity standard of at least 99 percent through reversed-phase high-performance liquid chromatography, while mass spectrometry confirms the observed mass against the theoretical value of the fatty-acid-modified tirzepatide backbone.
•📊3. Verified Sequence Specifications
| Compound Layout: | GLP-2 (Glucagon-Like Peptide-2) + Tirzepatide Blend Presentation |
| Dominant Formula: | C225H348N48O68 (Corresponding to the Tirzepatide Component) |
| Expected Molar Mass: | ~4814 g/mol |
| Reference Code / CAS: | DA-78491 (For Full Lot Traceability Records) |
| Purity Standards: | ≥99% Pure Confirmed via Analytical UV RP-HPLC Testing |
| Application Profile: | Synthesized Chemical Supplier Reagent for In-Vitro Research Only |
99% Purity Guaranteed
Independent Lab Tested
⚠️ FDA DISCLAIMER: These products are intended strictly for laboratory research use only. They are not intended for human consumption, diagnostic, or therapeutic purposes. The statements on this website have not been evaluated by the Food and Drug Administration.
